ERBB2 and breast carcinoma: Based on the results of DESTINY-Breast01 (NCT03248492)74, trastuzumab deruxtecan was approved by the U.S. FDA for patients with late stage HER2-positive breast cancer as second line treatment on December 20, 2019.